All day, every day we are flooded with 2020 presidential election coverage, but rarely do we get a nuanced analysis of how a new or continued administration will impact policies most important to health systems. In Part 1 of Sg2 Perspective’s 2-part election series, we discuss one such policy as Vizient Senior Government Relations and Policy Director Steve Rixen joins Sg2’s Bill Woodson and Valinda Rutledge to discuss how a Trump administration or a Biden administration would likely address high drug costs and what that means for health system providers.